Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Next Previous
X
Search
Trial Profile

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceralasertib (Primary) ; Trastuzumab-deruxtecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms DASH trial

    • Most Recent Events

    • 06 Jun 2024 Planned number of patients changed from 15 to 51.
    • 02 Jul 2021 Status changed from not yet recruiting to recruiting.
    • 02 Jul 2021 Planned End Date changed from 8 Mar 2023 to 31 Mar 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top